The UBS Oncology impact fund focuses on investing in the development of cancer therapeutics, with the primary goal of attractive financial returns. In addition, the fund is structured to make a positive global impact by helping to extend and improve the lives of cancer patients. The fund’s strategy is to invest primarily in small-sized companies, both public and private, through clinical “Proof of Concept” (PoC) trials designed to show whether a treatment has a benefit to cancer patients.
The fund is managed by MPM Oncology Impact Management LP (“MPM”), and is intended to leverage MPM’s strong brand, network, multi-disciplinary team and deep biomedical understanding of cancer to identify the most promising investment opportunities. It provides an opportunity for achieving attractive financial returns while also making a global impact, with 20% of MPM’s performance allocations (“carry”) from the Fund being contributed to non-profit organizations dedicated to cancer philanthropy. In addition, the Fund seeks to impose a 1% royalty on the future sale of drugs discovered and developed by its portfolio companies that will also be contributed to these philanthropic efforts.